Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acamprosate in Youth With Fragile X Syndrome
NCT01300923Phase 2Completed
- Sponsor
- Indiana University
- Start
- Aug 2010
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of acamprosate in Fragile X syndrome (FXS) (2 arms), sponsored by Indiana University. Primary endpoint: Clinical Global Impression-Severity Scale at 10 weeks. Started Aug 2010; status: completed.
02
Drugs
acamprosate
03
Conditions
Fragile X syndrome (FXS)
Beyond the preview
Go deeper on NCT01300923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01300923.